PT - JOURNAL ARTICLE AU - Yao, Xiang AU - Hu, Jingyi AU - Wang, Guangsong AU - Lin, Xiaoning AU - Sun, Jin AU - Dong, Guijiang AU - Kang, Junlong AU - Feng, Wei AU - Xie, Bowen AU - Huang, Yanlin AU - Tian, Xinhua AU - Chen, E. TI - Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory, Cognitive, and Athletic Implications after Multiple Injections of Gadolinium-Based Contrast Agents in Rats AID - 10.3174/ajnr.A8295 DP - 2024 Aug 01 TA - American Journal of Neuroradiology PG - 1153--1161 VI - 45 IP - 8 4099 - http://www.ajnr.org/content/45/8/1153.short 4100 - http://www.ajnr.org/content/45/8/1153.full SO - Am. J. Neuroradiol.2024 Aug 01; 45 AB - BACKGROUND AND PURPOSE: After repeat administration of gadolinium-based contrast agents (GBCAs), the association between gadolinium retention in the central and peripheral nervous systems and the main manifestations of myelopathy and progressive neurologic symptoms remains unclear. We investigated the effects of the repeat administration of GBCAs on gadolinium retention in the central and peripheral nervous systems and the sensory, cognitive, and athletic implications.MATERIALS AND METHODS: Forty-eight male Wistar rats (6 weeks of age) were randomly divided into 4 experimental groups (12 rats in each group): the gadodiamide group (linear and nonionic GBCAs), the gadopentetate dimeglumine group (linear and ionic GBCAs), the gadoterate meglumine group (macrocyclic and ionic GBCAs), and the control group (0.9% saline solution). The brains of the rats were scanned using 9.4T MRI. Sensory behavioral tests were performed to assess the effect of GBCAs on pain sensitivity function. Gadolinium deposition in the brain, spinal cord, and peripheral nerves was determined by inductively coupled plasma mass-spectrometry. Transmission electron microscopy was used to observe the microscopic distribution of gadolinium after deposition in the spinal cord. The histopathologic features in the spinal cord were analyzed by H&E staining, Nissl staining, glial fibrillary acidic protein staining, and neuron-specific enolase staining after administration of GBCAs.RESULTS: All GBCAs resulted in gadolinium deposition in the central and peripheral nerve tissues, with the highest deposition in the sciatic nerve tissue (mean, 62.86 [SD, 12.56] nmol/g). Decreased muscle power, impairment of spatial cognitive function power, and pain hypersensitivity to thermal and mechanical stimuli were observed after exposure to gadodiamide. At the spinal cord, transmission electron microscopy found that the region of gadolinium depositions had a spheric structure similar to “sea urchins” and was mainly located near the vascular basement membrane.CONCLUSIONS: Multiple injections of GBCAs caused gadolinium deposition in the brain, spinal cord, and peripheral nerves, especially in the spinal cords of the gadodiamide group. Gadodiamide led to pain hypersensitivity and decreased muscle power and cognitive ability. For the patients who are hypersensitive to pain and need multiple MRI examinations, we recommend using macrocyclic GBCAs and the lowest dose possible.DCNdeep cerebellar nucleusGBCAgadolinium-based contrast agentGdgadoliniumGFAPglial fibrillary acidic proteinICP-MSinductively coupled plasma mass-spectroscopyNSEneuron-specific enolaseNSFnephrogenic systemic fibrosisTEMtransmission electron microscopy